{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T06:10:12Z","timestamp":1756361412353,"version":"3.44.0"},"reference-count":39,"publisher":"BMJ","issue":"10","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["DTB"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:p>DTB drug reviews provide an overview of medicines that have been recently launched in the UK. The articles include a summary of the evidence of benefits and harms as well as details of the regulatory authority\u2019s assessment report.<\/jats:p>","DOI":"10.1136\/dtb.2020.000037","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T07:35:24Z","timestamp":1601364924000},"page":"151-156","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Three new drugs for the prevention of migraine"],"prefix":"10.1136","volume":"58","member":"239","published-online":{"date-parts":[[2020,9,28]]},"reference":[{"key":"2025082722565114000_58.10.151.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30322-3"},{"key":"2025082722565114000_58.10.151.2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2003.00568.x"},{"key":"2025082722565114000_58.10.151.3","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-015-0253-z"},{"key":"2025082722565114000_58.10.151.4","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0140-6736(19)32504-8","article-title":"Targeting calcitonin gene-related peptide: a new era in migraine therapy","volume":"394","author":"Charles","year":"2019","journal-title":"Lancet"},{"key":"2025082722565114000_58.10.151.5","unstructured":"Aimovig 70 mg solution for injection in pre-filled pen. Summary of Product Characteristics, EU. Novartis Europharm Limited, February 2020."},{"key":"2025082722565114000_58.10.151.6","unstructured":"Ajovy (fremanezumab) 225 mg pre-filled syringe for injection. Summary of Product Characteristics, EU. TEVA GmbH, November 2019."},{"key":"2025082722565114000_58.10.151.7","unstructured":"Emgality 120 mg solution for injection in pre-filled pen. Summary of Product Characteristics, EU. Eli Lilly Nederland B.V March 2020."},{"key":"2025082722565114000_58.10.151.8","unstructured":"British Association for the Study of Headache . National headache management system for adults [online]. 2019. Available: http:\/\/www.bash.org.uk\/downloads\/guidelines2019\/01_BASHNationalHeadache_Management_SystemforAdults_2019_guideline_versi.pdf [Accessed 06 August 2020]."},{"key":"2025082722565114000_58.10.151.9","unstructured":"Scottish Intercollegiate Guidelines Network, Health Improvement Scotland . Pharmacological management of migraine [online]. 2018. Available: https:\/\/www.sign.ac.uk\/sign-155-migraine [Accessed 06 August 2020]."},{"key":"2025082722565114000_58.10.151.10","unstructured":"The International Headache Society . The international classification of headache disorders 3rd edition [online]. 2018. Available: https:\/\/ichd-3.org\/1-migraine\/ [Accessed 06 August 2020]."},{"key":"2025082722565114000_58.10.151.11","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410381145"},{"key":"2025082722565114000_58.10.151.12","unstructured":"National Institute for Health and Care Excellence . Clinical Knowledge Summary - Migraine [online]. 2019. Available: https:\/\/cks.nice.org.uk\/migraine [Accessed 06 August 2020]."},{"key":"2025082722565114000_58.10.151.13","unstructured":"National Institute for Health and Care Excellence . Headaches in over 12s: diagnosis and management (CG150) [online]. 2015. Available: https:\/\/www.nice.org.uk\/guidance\/cg150 [Accessed 06 August 2020]."},{"key":"2025082722565114000_58.10.151.14","unstructured":"Joint Formulary Committee . British National formulary. Edition 79. London: BMJ Group and Pharmaceutical Press, 2020."},{"key":"2025082722565114000_58.10.151.15","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-015-0522-1","article-title":"New players in the preventive treatment of migraine","volume":"13","author":"Mitsikostas","year":"2015","journal-title":"BMC Med"},{"key":"2025082722565114000_58.10.151.16","unstructured":"National Institute for Health and Care Excellence . Botulinum toxin type A for the prevention of headaches in adults with chronic migraine (TA260) [online]. 2012. Available: https:\/\/www.nice.org.uk\/guidance\/ta260 [Accessed 06 August 2020]."},{"key":"2025082722565114000_58.10.151.17","unstructured":"Scottish Medicines Consortium . Botulinum toxin A (Botox) [online]. 2017. Available: https:\/\/www.scottishmedicines.org.uk\/medicines-advice\/botulinum-toxin-a-botox-resubmission-69211\/ [Accessed 06 August 2020]."},{"key":"2025082722565114000_58.10.151.18","unstructured":"European Medicines Agency . Guideline on clinical investigation of medicinal products for the treatment of migraine [online]. 2007. Available: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-medicinal-products-treatment-migraine_en.pdf [Accessed 06 August 2020]."},{"key":"2025082722565114000_58.10.151.19","unstructured":"European Medicines Agency . Aimovig [online]. 2019. Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/aimovig [Accessed 06 August 2020]."},{"key":"2025082722565114000_58.10.151.20","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30083-2"},{"key":"2025082722565114000_58.10.151.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705848"},{"key":"2025082722565114000_58.10.151.22","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418759786"},{"key":"2025082722565114000_58.10.151.23","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)00019-3"},{"key":"2025082722565114000_58.10.151.24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32534-0"},{"key":"2025082722565114000_58.10.151.25","unstructured":"European Medicines Agency . Ajovy [online]. 2019. Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ajovy [Accessed 06 August 2020]."},{"key":"2025082722565114000_58.10.151.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709038"},{"key":"2025082722565114000_58.10.151.27","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.4853"},{"key":"2025082722565114000_58.10.151.28","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","article-title":"Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (focus): a randomised, double-blind, placebo-controlled, phase 3B trial","volume":"394","author":"Ferrari","year":"2019","journal-title":"Lancet"},{"key":"2025082722565114000_58.10.151.29","unstructured":"European Medicines Agency . Emgality [online]. 2019. Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/emgality [Accessed 06 August 2020]."},{"key":"2025082722565114000_58.10.151.30","doi-asserted-by":"crossref","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","article-title":"Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled regain study","volume":"91","author":"Detke","year":"2018","journal-title":"Neurology"},{"key":"2025082722565114000_58.10.151.31","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2018.1212","article-title":"Evaluation of Galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial","volume":"75","author":"Stauffer","year":"2018","journal-title":"JAMA Neurol"},{"key":"2025082722565114000_58.10.151.32","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418779543"},{"key":"2025082722565114000_58.10.151.33","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-018-1193-2","article-title":"A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine","volume":"18","author":"Camporeale","year":"2018","journal-title":"BMC Neurol"},{"key":"2025082722565114000_58.10.151.34","unstructured":"ClinicalTrials.gov . A Study of galcanezumab (LY2951742) in adults with treatment-resistant migraine (CONQUER) [online]. 2020. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03559257 [Accessed 06 August 2020]."},{"key":"2025082722565114000_58.10.151.35","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-020-01097-3","article-title":"Understanding side-effects of anti-CGRP and anti-CGRP receptor antibodies","volume":"21","author":"Haanes","year":"2020","journal-title":"J Headache Pain"},{"key":"2025082722565114000_58.10.151.36","unstructured":"Scottish Medicines Consortium . Erenumab (Aimovig\u00ae) [online]. 2019. Available: https:\/\/www.scottishmedicines.org.uk\/medicines-advice\/erenumab-aimovig-full-submission-smc2134\/ [Accessed 06 August 2020]."},{"key":"2025082722565114000_58.10.151.37","unstructured":"Scottish Medicines Consortium . Fremanezumab (Ajovy\u00ae) [online]. 2019. Available: https:\/\/www.scottishmedicines.org.uk\/medicines-advice\/fremanezumab-ajovy-full-smc2226\/ [Accessed 06 August 2020]."},{"key":"2025082722565114000_58.10.151.38","unstructured":"National Institute for Health and Care Excellence . Fremanezumab for preventing migraine (TA631) [online]. 2020. Available: https:\/\/www.nice.org.uk\/guidance\/ta631 [Accessed 06 August 2020]."},{"key":"2025082722565114000_58.10.151.39","unstructured":"Institute for Clinical and Economic Review . Calcitonin gene-related peptide (CGRP) inhibitors as preventive treatments for patients with episodic or chronic migraine: effectiveness and value [online]. 2018. Available: https:\/\/icer-review.org\/material\/cgrp-final-report [Accessed 06 August 2020]."}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2020.000037","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T05:57:12Z","timestamp":1756360632000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2020.000037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,28]]},"references-count":39,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,9,28]]},"published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1136\/dtb.2020.000037"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2020.000037","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2020,9,28]]}}}